[Pharmacological treatment of diabetic retinopathy].
Chronic overproduction of growth hormone and insulin-like growth factor 1 play an important role in the pathogenesis of diabetic retinopathy. Somatostatin receptors are the targets of somatostatin analogues such as octreotide in the treatment of diabetic retinopathy. Octreotide has shown promise as a safe and effective treatment for advanced diabetic retinopathy and diabetic macular edema. One important pathomechanism in the development of diabetic complications is the activation of protein kinase C induced by high glucose due to an increased diacylglycerol level. The development of a selective PKCss inhibitor enables a new therapeutic approach for the treatment of diabetic retinopathy. Ongoing prospective clinical studies are investigating if treatment with specific PKCss inhibitors can prevent the progression of diabetic retinopathy and diabetic macular edema. The intravitreal injection of triamcinolone acetonide leads to at least temporary improvement of the diffuse diabetic macular edema. Side effects are increase of intraocular pressure, cataract, and endophthalmitis.
Lang
G E
GE
Augenklinik, Universitätsklinikum, Ulm. gabriele.lang@medizin.uni-ulm.de
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D018450:Disease Progression; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy; D015337:Multicenter Studies as Topic; D015282:Octreotide / Q000627:therapeutic use; D011446:Prospective Studies; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D013004:Somatostatin / Q000031:analogs & derivatives; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014822:Vitreous Body
D000893:Anti-Inflammatory Agents; D013004:Somatostatin; D011493:Protein Kinase C; D014222:Triamcinolone Acetonide; D015282:Octreotide